English
Home > Products > 330785-84-7

China 330785-84-7 Factory

Our primary goal is to offer our clients a serious and responsible business relationship, providing personalized attention to all of them for 330785-84-7,CAS NO 330785-84-7,Avanafil intermediate,Avanafil advance intermediate,5-PyriMidinecarboxylic acid, 4-[[(3-chloro-4-Methoxyphenyl)Methyl], Welcome all customers of home and abroad to visit our company, to forge a brilliant future by our cooperation.
330785-84-7, We've exported our solutions all over the world, especially the USA and European countries. Furthermore, all of our merchandise are manufactured with advanced equipment and strict QC procedures to ensure high quality.If you are interested in any of our products and solutions, please don't hesitate to contact us. We are going to try our best to meet your needs.

Related Products

Hot Products

  • Cyclopentanecarbaldehyde

    Cyclopentanecarbaldehyde

    Product Name:Cyclopentanecarbaldehyde
    Molecular Formula:C6H10O
    Molecular Weight:98.14
    CAS Registry Number:872-53-7
  • Spinosad

    Spinosad

    Product Name:Spinosad
    Molecular Formula:C41H65NO10
    Molecular Weight;731.96
    CAS Registry Number;168316-95-8
  • 5,6-Diethyl-2,3-dihydro-1H-inden-2-amine hydrochloride

    5,6-Diethyl-2,3-dihydro-1H-inden-2-amine hydrochloride

    Product Name:5,6-Diethyl-2,3-dihydro-1H-inden-2-amine hydrochloride
    Molecular Formula:C13H20ClN
    Molecular Weight:225.76
    CAS Registry Number:312753-53-0
  • 4-(Trifluoromethyl)benzaldehyde

    4-(Trifluoromethyl)benzaldehyde

    Product Name:4-(Trifluoromethyl)benzaldehyde
    Molecular Formula:C8H5F3O
    Molecular Weight:174.12
    CAS Registry Number:455-19-6
  • Rapamycin

    Rapamycin

    Product Name:Rapamycin
    Molecular Formula:C51H79NO13
    Molecular Weight;914.17
    CAS Registry Number;53123-88-9
  • Sugammagex

    Sugammagex

    Product Name:Sugammadex
    Molecular Formula:C72H112O48S8
    Molecular Weight;2002.15
    CAS Registry Number;343306-71-8
  • Related Blog
  • Reviews

  • What are the raw materials required for pharmaceutical industry?

    Pharmaceutical industry has a lot of constraints and specialties which make it stand on a completely differents scale than any other industries. Being closely related to the medical field and also complementary to it, the pharmaceutical industry needs utmost care and precision in each and every aspect of the field ranging from collecting the raw materials to getting the final product ready for supply in the market.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

  • CAS No. 144689-24-7 Olmesartan Introduction

    Olmesartan is an angiotensin II receptor blocker, widely used for the treatment of hypertension. The Renin-Angiotensin-Aldosterone System (RAAS) plays an importent role in the development and progression of many diseases such as hypertension...

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    Here are so many diseases that affect the human population in the current hours and so are the numerous drugs that are available to treat those diseases.

  • How is a drug produced?

    ​There are so many different drugs ,with different color /shape ( like capsule ,tablet or Infusion) and price . Here we would like to explain , what makes it so different? How is a drug produced?

  • Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

    Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

Related Search

CAS NO 330785-84-7

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept